A phase 1 trial (NCT03262103) testing the safety of a personalized vaccine approach for locally advanced oligometastatic prostate cancer has shown promising results. The vaccine, developed from biopsied prostate cancer cells and administered via intratumoral plus systemic intramuscular injection of poly-ICLC, was well tolerated and demonstrated potential in inhibiting metastases, enabling localized treatment with curative intent.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.